Jonathan Tietz, Jason Mock, and Kristel Schorr of Foley & Lardner offer their thoughts on patent procurement and licensing for COVID-19-related technologies.
Richard Fawcett, senior associate at Powell Gilbert, outlines why the UK patent system poses no obstacle to the UK government’s rallying call for ventilator production amid the COVID-19 pandemic.
One of the perennial inherent challenges for legislators and regulators is crafting laws and regulatory frameworks that are firm enough to deal with the issues of the present, but flexible enough to cater for the challenges of the future, as Daniel Lim and Anna Jackson of Kirkland & Ellis explain.
The next event in ACI’s Women Leaders in Law series, on July 25 & 26 in Boston, brings together in-house and private practice professionals from the pharmaceutical, biotechnology, and medical device industries.
Precision medicine is an evolving field, which takes individual variability in genes, environment, and lifestyle into account when tackling disease treatment and prevention. LSIPR reports.
Two references to the Court of Justice of the European Union should help clarify the position on what exactly is eligible for a supplementary protection certificate, as Michael Pears and Joel Beevers of Potter Clarkson explain.
Brazil’s patent law does not allow methods of treatment to be patented, but there are other means of getting protection, according to Kene Gallois and Samantha Salim of Daniel Law.
The development of precision treatments must be complemented by the development of precision diagnostics, as Daniel Lim of Kirkland & Ellis explains.
With several major drugs set to face generic or biosimilar competition as patent protection expires, LSIPR analyses how well prepared their manufacturers are and how badly their sales may be affected.
Samsung and HP are just two technology companies that have diversified and invested in the life sciences industry. What impact will this type of activity have on the sector and will it be beneficial in the long run? LSIPR finds out.